世紀華通(002602.SZ):公司投資的生態企業旗下《注意力強化訓練軟件》獲得二類醫療器械證,正積極嘗試應用對接各種腦機接口
格隆匯5月31日丨有投資者在投資者互動平台向世紀華通(002602.SZ)提問,“公司與浙江大學的腦機接口目前進展如何?未來如何進行知識產權量化?有沒有產業化規劃?”
公司回覆稱,公司與浙江大學於2020年共建了浙江大學傳奇創新研究中心,主要聚焦數字醫藥、數字器官、腦機融合等新興領域。去年,傳奇中心研究團隊在腦疾病調控機制研究方面取得重大突破,相關成果分別被國際頂級期刊《自然(Nature)》雜誌刊登以及作為封面論文被髮表在了全球頂級神經學雜誌《自然神經科學(nature neuroscience)》上。此外公司投資的生態企業,旗下《注意力強化訓練軟件》獲得國家藥品監督管理局二類醫療器械證,正積極嘗試應用對接各種腦機接口。後續具體相關進展請關注公司披露的信息。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.